Sign In
Buy CNTB
$1.99
-0.0100 (-0.500%)
At Close: Jun 22, 2026
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balan
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
12:05am, Friday, 22'nd May 2026
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
04:05pm, Tuesday, 12'th May 2026
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transfo
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
09:00am, Tuesday, 12'th May 2026
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma: New Market Opportunity In The Emergency Setting
10:08am, Wednesday, 29'th Apr 2026
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on trans
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
04:05pm, Tuesday, 31'st Mar 2026
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-b
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Connect Biopharma Announces $20.2 Million Private Placement Financing
07:02am, Monday, 30'th Mar 2026
Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (�
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
07:01am, Monday, 30'th Mar 2026
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients –
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many patients experienci
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:26am, Wednesday, 11'th Mar 2026
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are presently coverin
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect, or the Company), a clinical-stage biopharmaceutical company focused on tran
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference
09:00am, Tuesday, 03'rd Mar 2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compa
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference
05:04am, Monday, 02'nd Mar 2026
Connect Biopharma (NASDAQ: CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it
